Repare Therapeutics Inc (RPTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Repare Therapeutics Inc (RPTX) has a cash flow conversion efficiency ratio of 0.023x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.65 Million) by net assets ($115.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Repare Therapeutics Inc to measure how much of total assets are equity-financed.
Repare Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Repare Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Repare Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
Repare Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Repare Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thien Viet Securities JSC
VN:TVS
|
0.356x |
|
ELEMENT 29 RESOURCES INC
F:2IK
|
-0.018x |
|
WMG Holdings Bhd
KLSE:6378
|
0.065x |
|
IRM ENERGY LTD
NSE:IRMENERGY
|
0.085x |
|
Safari Investments RSA Ltd
JSE:SAR
|
0.015x |
|
Wooriro Co. Ltd
KQ:046970
|
-0.001x |
|
Lang Inc
TW:6165
|
0.065x |
|
Pang Rim Spinn
KO:003610
|
0.002x |
Annual Cash Flow Conversion Efficiency for Repare Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Repare Therapeutics Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Repare Therapeutics Inc (RPTX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $151.13 Million | $-76.44 Million | -0.506x | +15.64% |
| 2023-12-31 | $212.08 Million | $-127.16 Million | -0.600x | -52146.58% |
| 2022-12-31 | $279.52 Million | $322.00K | 0.001x | +100.39% |
| 2021-12-31 | $288.42 Million | $-85.80 Million | -0.297x | -1302.41% |
| 2020-12-31 | $286.83 Million | $-6.08 Million | -0.021x | +89.66% |
| 2019-12-31 | $89.87 Million | $-18.43 Million | -0.205x | -136.38% |
| 2018-12-31 | $-22.38 Million | $-12.62 Million | 0.564x | -- |
About Repare Therapeutics Inc
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camo… Read more